These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34950253)

  • 1. N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer.
    Lu M; Zhan H; Liu B; Li D; Li W; Chen X; Zhou X
    EPMA J; 2021 Dec; 12(4):589-604. PubMed ID: 34950253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer.
    Yue Q; Zhang Y; Bai J; Duan X; Wang H
    Dis Markers; 2022; 2022():7765900. PubMed ID: 35774851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
    Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Prognostic Markers of N6-Methylandenosine-Related Noncoding RNAs in Non-Small-Cell Lung Cancer.
    Zhang Z; Li J; Lu K; Wu W; Huang Z; Zhang C; Guo W; Li J; Lin L
    J Oncol; 2022; 2022():3657349. PubMed ID: 35401751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics of m
    Han X; Chen Y; Xie J; Wang Y
    J Cancer; 2023; 14(15):2919-2930. PubMed ID: 37781080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response.
    Cao J; Liang Y; Gu JJ; Huang Y; Wang B
    Front Genet; 2022; 13():991162. PubMed ID: 36353118
    [No Abstract]   [Full Text] [Related]  

  • 12. The development of a novel signature based on the m
    Li H; Lin D; Wang X; Feng Z; Zhang J; Wang K
    Front Genet; 2022; 13():894080. PubMed ID: 36313417
    [No Abstract]   [Full Text] [Related]  

  • 13. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
    Wu J; Cai Y; Zhao G; Li M
    J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
    Huang X; Wang HF; Huang S
    Front Genet; 2022; 13():906880. PubMed ID: 36061188
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of potential novel N6-methyladenosine effector-related lncRNA biomarkers for serous ovarian carcinoma: a machine learning-based exploration in the framework of 3P medicine.
    Ye L; Tong X; Pan K; Shi X; Xu B; Yao X; Zhuo L; Fang S; Tang S; Jiang Z; Xue X; Lu W; Guo G
    Front Pharmacol; 2024; 15():1351929. PubMed ID: 38895621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 17. [Correlation analysis of Poor Prognosis and Immunotherapy of lncRNAs Related with m
    Gu R; Liu M; Lin P; Feng TY; Yuan H; Ou DQ; Li SQ; Li Q; Zhao G; Zhang J; Li K
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jul; 53(4):626-636. PubMed ID: 35871733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
    Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
    Front Oncol; 2021; 11():710767. PubMed ID: 34458149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
    Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
    BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.